Recombinant Mouse TNFRSF17/BCMA Protein (His & Fc Tag)(Active)
SKU: PKSM040938-100
Recombinant Mouse TNFRSF17/BCMA Protein (His & Fc Tag)(Active)
| SKU # | PKSM040938 |
| Expression Host | HEK293 Cells |
Description
| Synonyms | B-cell maturation protein, BCM, BCMA, CD269, Tnfrsf13, Tnfrsf13a, Tnfrsf17, Tumor necrosis factor receptor superfamily member 17 |
| Species | Mouse |
| Expression Host | HEK293 Cells |
| Sequence | Met 1-Thr 49 |
| Accession | NP_035738.1 |
| Calculated Molecular Weight | 33.7 kDa |
| Observed Molecular Weight | 35-48 kDa |
| Tag | C-His-Fc |
| Bio-activity | Immobilized human BAFF at 10 μg/ml (100 μl/well) can bind mouse BCMA-Fch, The EC50 of mouse BCMA-Fch is 0.02-0.06 μg/mL. |
Properties
| Purity | > 90 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
Background
Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.